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Background: Severe neonatal jaundice and its progression to kernicterus is a leading cause of death and disability
among newborns in poorly-resourced countries, particularly in sub-Saharan Africa. The standard treatment for jaundice
using conventional phototherapy (CPT) with electric artificial blue light sources is often hampered by the lack of
(functional) CPT devices due either to financial constraints or erratic electrical power. In an attempt to make
phototherapy (PT) more readily available for the treatment of pathologic jaundice in underserved tropical regions,
we set out to test the hypothesis that filtered sunlight phototherapy (FS-PT), in which potentially harmful ultraviolet
and infrared rays are appropriately screened, will be as efficacious as CPT.
Methods/design: This prospective, non-blinded randomized controlled non-inferiority trial seeks to enroll infants with
elevated total serum/plasma bilirubin (TSB, defined as 3 mg/dl below the level recommended by the American Academy
of Pediatrics for high-risk infants requiring PT) who will be randomly and equally assigned to receive FS-PT or CPT for a
total of 616 days at an inner-city maternity hospital in Lagos, Nigeria. Two FS-PT canopies with pre-tested films will be
used. One canopy with a film that transmits roughly 33% blue light (wavelength range: 400 to 520 nm) will be used
during sunny periods of a day. Another canopy with a film that transmits about 79% blue light will be used during
overcast periods of the day. The infants will be moved from one canopy to the other as needed during the day with
the goal of keeping the blue light irradiance level above 8 μW/cm2/nm.
Primary outcome: FS-PT will be as efficacious as CPT in reducing the rate of rise in bilirubin levels. Secondary outcome:
The number of infants requiring exchange transfusion under FS-PT will not be more than those under CPT.
Conclusion: This novel study offers the prospect of an effective treatment for infants at risk of severe neonatal jaundice
and avoidable exchange transfusion in poorly-resourced settings without access to (reliable) CPT in the tropics.
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Severe neonatal jaundice (NNJ) or hyperbilirubinemia
and its progression to acute bilirubin encephalopathy
(ABE) and kernicterus is a leading, yet preventable, cause
of newborn re-hospitalizations, deaths, and disabilities glo-
bally [1-5]. Phototherapy (PT), which involves exposing a
newborn’s skin to electric lamp-generated blue light, is the
standard treatment for removing excessive bilirubin, ex-
cept in extreme cases when exchange transfusion becomes
necessary [6].
Numerous studies from poorly-resourced countries
suggest that severe NNJ represents perhaps the largest
unrecognized cause of neonatal morbidity and mortality
in the world [4,7]. In sub-Saharan Africa, especially in
Nigeria and Kenya, NNJ is a leading cause of death in
newborn nurseries [8-13] and long-term neurological
impairment in survivors [14-18]. Unfortunately, PT may
not be available in these countries because of the lack of
devices and/or of reliable electrical power [19,20]. In
these areas, modern PT devices are not readily affordable,
often break down because of electrical power surges, and
are difficult to maintain due to the unavailability of re-
placement parts. Even where PT devices are available,
most hospitals lack the resources necessary to replace
fluorescent lamps, which is recommended after 2,000 to
3,000 hours of use, and, as a consequence, simply leave in-
effective tubes in place until they burn out. Moreover, very
few hospitals have appropriate irradiance meters for meas-
uring the intensity of the blue light emitted by the lamps,
resulting in few or no devices providing the optimal level
of irradiance required for intensive (>30 μW/cm2/nm)
conventional phototherapy (CPT) [21,22]. However, it is
not uncommon, especially in areas without access to CPT,
for the parents/guardians of jaundiced infants to place
their babies in direct sunlight unaware of the potential
harm or safety risks.
The scientific potential of sunlight as a possible treat-
ment for NNJ was first demonstrated by Cremer and
colleagues in 1958 [23]. His team found that placing
naked infants in sunlight decreased bilirubin levels. This
observation led to the production of the first PT device
using fluorescent blue light tubes. These early studies
subsequently led to the development of commercially
available, easily controlled, electricity-requiring artificial
blue light sources for effective, on-demand PT of new-
borns in industrialized countries. The potential efficacy
of direct sunlight PT compared with CPT has also been
demonstrated in an in vitro study [24].
Using direct sunlight for PT has a number of clinical
and practical drawbacks that could make its use undesir-
able. Sunlight contains altitude-, seasonal-, and time-of-
day-dependent levels of harmful ultraviolet A, B, and C
radiation, which can seriously and permanently damage
human skin. It also contains significant levels of warminginfrared radiation, which, in the absence of sufficient cool-
ing, could raise core body temperatures to unsafe levels.
However, several technological solutions exist for filtering
unwanted radiation from any light source, including sun-
light, while preserving the desirable attributes of a given
energy spectrum [25]. When filtered to exclude the harm-
ful spectral radiation, the use of sunlight can be valuable in
environments that have no access to electric lamp PT.
The most practical filters of sunlight are the commer-
cially available window-tinting films, widely used in vehi-
cles and residential and commercial structures in sunny
climates. Although window-tinting films are traditionally
affixed to a glass surface, these films can also be stretched
over a support frame, under which an infant basket
(Figure 1A), bassinet, or crib (Figure 1B) can be placed.
Our preliminary laboratory bench studies in California
and field studies in Nigeria have shown that such films
effectively remove potentially harmful radiation, while
allowing the transmission of beneficial blue light re-
quired for effective PT. The levels of irradiance recorded
exceeded that delivered by the most potent newborn PT
devices. In one of the field tests in a rural hospital in
Nigeria, seven jaundiced infants were placed under port-
able individual or group filtered sunlight PT (FS-PT)
using film-covered canopies placed in direct sunlight in
the hospital courtyard (Figure 1B,C). Body temperature
and blue light irradiance were monitored every hour, and
the infants were watched closely for the development of
clinical dehydration and sunburn. FS-PT was tolerated
well by both newborns and their mothers and allowed for
maternal bonding during treatment. None of the infants
developed significant hypothermia (defined as <35.5°C),
and displayed no evidence of dehydration or sunburn.
Six of the infants had at least one temperature epi-
sode >38.0°C during their course of FS-PT, but none
exceeded 39°C, and all recovered after being returned
indoors. The average time to being able to return to
FS-PT was 19.7 minutes, with only two instances over
60 minutes. Moreover, placing infants on a moistened
towel during high ambient temperatures (>40°C) quite
readily maintained body temperatures of infants in cribs.
Observational study on the safety and potential efficacy
of filtered sunlight phototherapy
A recent comprehensive systematic review of available
evidence worldwide on PT found no randomized con-
trolled trials (RCTs) dealing with either sunlight or en-
vironmental light [26]. Prior to our proposed RCT to
establish the effectiveness of FS-PT compared with CPT
in a larger sample of infants, we conducted an observa-
tional study to evaluate safety and potential efficacy of
two previously tested films for use in an inner-city mater-
nity hospital in Lagos, Nigeria. FS-PT safety was deter-
mined through close monitoring of infant temperature,
Figure 1 Filtered sunlight canopies. A: Experimental filtered sunlight canopy with a baby doll; B: Baby placed under a filtered sunlight canopy
in an open lawn in a primary care setting; C: Mother-infant pairs with health workers under a group filtered sunlight canopy in a hospital setting.
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Therapy was deemed safe on a given day if the infant did
not have to be removed from phototherapy due to needing
physician treatment for sunburn or dehydration, due to
persistent temperature instability defined as two or more
episodes of temperatures <35.0 or >39.0°C, or due to fail-
ure to return to normothermia (defined as 35.5 to 38.0°C)
within 1 hour of being removed from FS-PT. Efficacy was
evaluated by measuring the rate of rise/decline in total
serum/plasma bilirubin (TSB) levels. Treatment was
deemed safe and efficacious if the infant was able to stay
in the FS-PT canopy for ≥5 hours per day and the rate of
rise of TSB was <0.2 mg/dl/hour for infants ≤72 hours of
age or if TSB decreased for infants >72 hours of age. This
study was concluded in August 2012, details of which are
scheduled for publication shortly. In summary, 203 term
and near-term newborns (≤14 days old) with clinically sig-
nificant jaundice as assessed by TSB levels were enrolled.
They received treatment under a FS-PT canopy over a
period of 227 days. Hourly measurements of axillary body
temperatures and monitoring of sunburn, dehydration,
and irradiances of FS-PT were performed. The results
showed that FS-PT was efficacious in 94% (164/175) of
the infants studied. Average irradiance from FS-PT was
37 ± 14 (range 8 to 65) μW/cm2/nm as measured by the
Bili-Blanket Meter II© (General Electric, Fairfield, CT,USA). No infant developed sunburn or dehydration, nor
met exclusion criteria. Based on these favorable findings
with our selected films (Gila Titanium and Air Blue 80 pro-
duced by CP Films Inc. Subsidiary of Eastman Chemical
Co. Fieldale, VA, USA), we set out under the second phase
of this project to demonstrate primarily in a RCT that FS-
PT is just as efficacious as CPT in the treatment of infants
with or at risk of severe NNJ.Methods/design
Aims and hypotheses
The primary goal of this study is to demonstrate that the
efficacy of FS-PT is no worse than that of CPT, with a
non-inferiority margin of 10%. In effect, our null hypoth-
esis is that this margin is above 10% suggesting that FS-
PT is inferior to CPT.
The secondary goal of the study is to demonstrate that
the proportion of infants who require exchange transfusion
under FS-PT is no worse than that under CPT, with a non-
inferiority margin of 5% based on a clinical rationale that
FS-PT is non-inferior to CPT and still better than no treat-
ment. This was also informed by the results of a meta-
analysis of RCTs comparing CPT with no treatment which
estimated that 10 infants needed to be treated with CPT to
prevent an exchange transfusion [26].
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This is a prospective, non-blinded, single center, ran-
domized two-stage controlled non-inferiority clinical
trial. During the first stage of the study, infants will be
referred from elevated transcutaneous bilirubin (TcB)
screening and enrolled for the definitive TSB estimation.
Only infants with significantly elevated TSB levels will
qualify for inclusion into the second stage of the study
for PT treatment and will be randomly assigned to re-
ceive FS-PT or CPT.
Study setting
The study location is Island Maternity Hospital (IMH),
Lagos, Nigeria, which is a state-owned hospital. It
has a special care baby unit with CPT and other basic
neonatal care facilities, including intravenous (IV) fluids,
antibiotics, and exchange transfusion. Ventilator sup-
port and pumps for giving IV fluids are not avail-
able. It is a 180-bed residency teaching hospital with
about 300 deliveries per month of which 45 infants
(15%) would be expected to qualify for PT. It is pos-
sible at this location to give routine care, IV fluids,
antibiotics, oxygen, and medications without inter-
rupting PT. The average maximum temperature in
Lagos is 32°C (90°F) during the dry season (November
to March), with a maximum recorded temperature of
40°C (104°F), making FS-PT possible even with infants
unclothed or minimally clothed. In the rainy season it
should be possible to maintain satisfactory irradiances
in the absence of an excessively overcast sky. This site
was chosen for the maiden study to ensure that back-
up neonatal care services are readily available when
required until we have the required safety and efficacy
data.
Definition of high-risk threshold
All jaundiced infants with elevated TSB, defined as
3 mg/dl below the level recommended by the American
Academy of Pediatrics (AAP) [27] for PT in high-risk
infants, will be considered at high risk. The high-risk
classification category of the AAP guideline was selected
because laboratory evaluation for hemolysis will not be
consistently available during the study, and Nigerian in-
fants are known to be at higher risk for severe NNJ sec-
ondary to glucose-6-phosphate dehydrogenase (G6PD)
deficiency [28]. This TSB level was chosen also because
many hospitals begin PT about 2 to 3 mg/dl below the
current level in the United States, due to the severity of
NNJ and the sub-optimal PT treatment in most locations
in Nigeria.
Primary outcome
The primary outcome for the RCT is efficacy of FS-PT
compared with CPT.Evaluation criteria
Change in TSB level per hour of therapy defined as a
binary variable. The TSB level will be measured immedi-
ately before beginning therapy on a given day and imme-
diately after therapy is completed that day, and the
change in bilirubin level in mg/dl per hour of therapy
will be calculated. For infants who are less than 72 hours
old in the morning, the treatment will be judged effica-
cious if the bilirubin level rises more slowly than 0.2 mg/dl
per hour of therapy that day. For infants who are more
than 72 hours old, the treatment will be judged efficacious
if the bilirubin level falls. Efficacy will be evaluated only
for days in which the treatment was deemed safe (that is,
when the infant did not have to be removed from PT due
to a need for physician treatment for sunburn or de-
hydration, persistent temperature instability defined as
two or more episodes of temperatures <35.0 or >39.0°C,
or failure to return to normothermia (defined as 35.5 to
38.0°C) within 1 hour of being removed from PT). The
average efficacy of each type of PT, defined as the propor-
tion of safe days where a given therapy was used in which
the therapy was efficacious, will be compared. FS-PT will
be considered at least as efficacious as CPT if the average
efficacy on days where FS-PT was used is no worse than
10% less than the average efficacy on days where CPT
was used.
Secondary outcome
A secondary outcome for this trial is the proportion of
enrolled infants who require exchange transfusion. FS-PT
will be considered at least as efficacious as CPT if the pro-
portion of infants who require exchange transfusion under
FS-PT is no more than 5% greater than the proportion
under CPT.
Sample size
The minimum sample size was estimated using the fol-
lowing assumptions: 1) the average efficacy of CPT is
80%; 2) the average efficacy of FS-PT is 80%; 3) there
will be the same number of infants assigned to both
groups; 4) the delta value is 10% - that is, we want to
demonstrate that FS-PT is no more than 10% worse
than CPT; and 5) 80% power, one-sided alpha = 0.025.
Under these assumptions, a total of 504 days, or 252
days in each treatment group, will be required. This cal-
culation gives the required number of treatment days
that are evaluable for efficacy. Since efficacy will be eval-
uated only for days in which the treatment was deemed
safe, the sample size was increased to account for the
possibility that the proportion of safe days might be as
low as 90%. Assuming that the safety of both FS-PT and
CPT is 90%, a sample size of 560 total days is required.
Assuming that a typical course of treatment lasts 1 day,
both for FS-PT and CPT, then 560 infants, or 280 infants
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loss due to rainy days (in the FS-PT group), delisting of
infants by parents or guardians, or missing data (in both
groups), we will enroll 616 infants, or 308 infants in each
group. From our year 1 data in the preceding observa-
tional study only 66% of the 826 infants referred for ele-
vated TcB had significant elevated TSB levels, hence 915
infants or more will be enrolled for stage 1 bilirubin esti-
mation until the total requirement of 560 treatment days
is reached (Figure 2).
Subject recruitment
Infants born in the hospital will be screened daily from 0
to 14 days of life for elevated TSB using TcB measure-
ments, while in the hospital or, if discharged before 14
days, in the community by nurses sent out from the hos-
pital when possible. Infants from the community will
also be screened if within 14 days they choose to come
to the study site for screening. The parents will be asked
to return with their infants to the hospital if the parent
observes new-onset jaundice between 1 and 14 days of
life. If the TcB is not elevated during the first 14 days of
life, the subject will cease to be eligible for the study. If
the TcB is elevated and the other study inclusion and ex-
clusion criteria are met, then the infant will be recruited
for the study after informed consent in writing or thumb
printing is obtained from a parent or guardian. The in-
fant will then have a TSB measured. Enrolled infants
with elevated TSB (defined as 3 mg/dl below the level
recommended by the AAP [27] to begin PT in high-risk
infants) will be randomly assigned to receive FS-PT or
CPT. Enrolled infants with TSB levels that are not elevated
as defined above will not be treated with PT. They will






Figure 2 Enrolment flow chart. CPT, conventional phototherapy; FS-PT, f
serum/plasma bilirubin.above. If their subsequent TcB levels are not elevated dur-
ing the first 14 days of life, the infant will be withdrawn
from the study.
Subject screening
Screening criteria prior to enrolment are shown in
Table 1.
Prior and concomitant therapy
All infants who meet the AAP guideline for the initiation
of PT will be treated with CPT at night or when it is not
possible to use FS-PT, secondary to rain or overcast sky.
CPT will be performed per hospital standards. Addition-
ally, since the study physicians only serve as consultants
for patients requiring treatment for NNJ, patient man-
agement decisions, including the need for and timing
of exchange transfusion, administration of antibiotics or
other testing, will be at the discretion of the attending
physician. AAP guidelines will be used to direct the deci-
sion of when to perform exchange transfusion, but the
final decision will be that of the attending physician.
Generally, exchange transfusion is performed in any
term infant in Nigeria whose TSB level is ≥20 mg/dl or
in any infant with neurologic signs of ABE, regardless of
the recommendations in the AAP guideline.
Inclusion criteria
Subjects will be eligible to participate in the study if all
of the following conditions exist:1) at time of birth,
infant is ≥35 weeks gestation (or >2.2 kg if gestational
age is not available); 2) infant is ≤14 days old at the time
of enrollment; 3) at time of enrollment, infant has an ele-
vated TcB defined as 3 mg/dl below the level recom-
mended for high-risk infants per AAP guideline or higher;Screening








continue with daily 
TcB
iltered sunlight phototherapy; TcB, transcutaneous bilirubin; TSB, total
Table 1 Screening criteria prior to enrolment
Test Screening requirement
Gestational age and/or weight Greater than or equal to 35 weeks gestation (or >2.2 kg if gestational age is not available).
Infant must be ≤14 days old at the time of first PT.
TcB Screened daily for the first 7 days of life if in hospital and, when possible, in the community
if discharged before 7 days of life or if the patient chooses to come in for screening up
to14 days of life. If the TcB is elevated (elevated will be defined as a point 3 mg/dl below
that recommended by the AAP for PT in high risk infants and above) at any time during
the first 14 days of life, a TSB will be done.
Physical examination (dehydration, oxygen use,
ABE, life expectancy, sunburn)
Subjects cannot be dehydrated, sunburned, using oxygen, or have ABE or a life expectancy
<24 hours at the time of examination by the physician for enrollment in the treatment
phase of the protocol.
AAP, American Academy of Pediatrics; ABE, acute bilirubin encephalopathy; PT, phototherapy; TcB, transcutaneous bilirubin; TSB, total serum/plasma bilirubin.
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participate.
Exclusion criteria
Subjects will be excluded from participation in the study
if any of the following conditions exist at the time of en-
rollment:1) infants with a condition requiring referral for
treatment not available at the hospital study site and/or
CPT unit; 2) infants with a life-expectancy of <24 hours;
3) infants requiring oxygen therapy; 4) infants clinically
dehydrated or sunburned; 5) infants with a temper-
ature <35.5°C or >38°C; 6) infants with ABE on clinical
examination; 7) infants meeting the criteria for exchange
transfusion.
Inclusion and exclusion criteria are only applicable at
the time of enrollment before randomization to prevent
bias of the treatment comparison.
Exit/discontinuation/withdrawal criteria
Subjects will exit the study (will cease to receive FS-PT
or CPT) if any of the following conditions occur: 1) per-
sistent temperature instability defined as two or more
episodes of temperatures <35.0°C or >39.0°C; 2) failure
to return to normothermia (defined as 35.5°C to 38.0°C)
within 1 hour of being removed from PT; 3) physician
treatment for dehydration or sunburn is required; 4) TSB
level reaches exchange transfusion levels; 5) inter-current
illness not compatible with PT or needing more care
than can be provided in the FS-PT canopy or CPT ward;
6) infants requiring transfer to another hospital; 7) parent
request; 8) subject death; 9) subject completes the proto-
col (TcB or TSB level is no longer elevated); 10) subject’s
well-being, in the opinion of the Investigator, would be
compromised by study continuation; 11) Institutional
Review Board (IRB) recommendation; or 12) subject’s risk
level indicates PT should be stopped.
Infants who have been withdrawn from the study will
have a physical examination and a final TcB. Safety data
will be analyzed for all days in which the subjects spend
any time under either FS-PT or CPT.Efficacy will be evaluated for all days in which the
treatment was deemed safe (that is, when the infant did
not have to be removed from PT due to a need for phys-
ician treatment for sunburn or dehydration, due to per-
sistent temperature instability defined as two or more
episodes of temperatures <35.0 or >39.0°C, or due to
failure to return to normothermia (defined as 35.5 to
38.0°C) within 1 hour of being removed from PT).
Randomization scheme
Enrolled infants with elevated TSB (defined as 3 mg/dl
below the level recommended by the AAP to begin PT in
high-risk infants) will be randomly assigned to receive FS-
PT or CPT. A block randomization procedure with vari-
able block sizes will be used to maximize unpredictability.
The randomization assignments of FS-PT or CPT will be
printed on sequentially numbered sheets of paper and
enclosed in opaque, sealed, sequentially numbered enve-
lopes. The sealed envelopes will be prepared indepen-
dently by the study statistician based in the USA and
transported to Nigeria by the regulatory sponsor. When
an enrolled infant’s TSB level is obtained and found to be
3 mg/dl or more below the AAP threshold for high-risk
infants the study nurse will request the next envelope.
The envelope will be opened and both the envelope num-
ber and the treatment assignment will be recorded on the
case report form. The laboratory technician responsible
for measuring the serum bilirubin level will be unaware of
the sequence of treatment allocation of either FS-PT or
CPT for each eligible infant and will not be involved in ad-
ministering PT. The study will not be blinded as it is not
physically possible to blind either the participating infants
or parents, nor the hospital personnel.
Laboratory testing procedures
Glucose-6-phosphate dehydrogenase
Because of the high prevalence of G6PD deficiency in our
study population, enrolled infants will be routinely
screened for this condition using simple and inexpensive
supplies. The method will be based on the fluorescent
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[29]. This test has been considered a standard method of
G6PD screening especially in resource-poor settings,
since inexpensive reagents and materials can be used.
Bilirubin
TSB will be estimated using standard methods. Hematocrit
testing will be done using standard laboratory methods.
Coombs testing and blood typing
Coombs testing and blood typing will be performed in
the blood bank laboratory at IMH.
Specimen collection
Blood specimens for TSB measurements will generally
be collected by heel-stick. Specimens for G6PD, blood
type and Rh will be drawn by venipuncture.
Clinical procedures
Criteria for admission
Infants born in the hospital will be screened daily from 0
to 14 days of life for elevated TcB while in the hospital or,
if discharged before 14 days, in the community by nurses
sent out from the hospital when possible. Infants ≤14 days
old from the community presenting to the study site will
also be screened. The parents will be asked to return with
their infant to the hospital if the parent observes new on-
set jaundice between 1 and 14 days of life.
Screening
During the screening period, information about the baby
and the mother will be collected. TcB testing will be
done for up to 14 days, using Minolta AirShields
Jaundice Meter JM-103 (Draeger Medical Systems, Inc.,
Telford, PA, USA) either in the hospital or in the com-
munity. If the TcB is not elevated during the first 14 days
of life, the subject will not be eligible for the study. If at
any time during screening the infant’s TcB level rises to
within 3 mg/dl below the AAP threshold [27] for high-
risk infants, inclusion/exclusion criteria will be reviewed.
If the infant is eligible, the infant will be recruited for
the study. The infant’s mother and/or father will be
approached to ask if they are interested in participating in
the research study. If they are willing, the consent form for
the study will be discussed. If informed consent is given to
participate, consent will be documented on the consent
form in writing or thumb printing.
Pre-treatment (stage 1)
The enrolled infant will then have a TSB drawn (stage 1)
using the Advanced Bilirubinometer Stat-Analyzer, Model
BR2 (Advanced Instruments, Inc, Norwood, MA, USA)
before treatment (stage 2). Enrolled infants with elevated
TSB qualify for inclusion into the second stage of thestudy and will be randomly assigned to receive FS-PT or
CPT. Enrolled infants with TSB levels that are not elevated
as defined above will not proceed to the second stage to
be treated with PT. However, they will continue to be
screened for elevated TcB as described above. If their sub-
sequent TcB levels are not elevated during the first 14 days
of life, the infant will be withdrawn from the study. All in-
fants who meet the AAP guideline for the initiation of PT
will be treated with CPT at night or when it is not possible
to use FS-PT, secondary to rain or excessive cloud cover
(defined as cloud cover persisting for more than 2 hours).
FS-PT will be optimized in all infants by using white cloth
lining the bottom and sides of the cot and exposing the in-
fant maximally. CPT will be performed per international
standards of practice [27].
Treatment (stage 2)
FS-PT will be started in the morning after the irradiance
level inside the canopy is at least 8 μW/cm2/nm, and
will be stopped in the late afternoon when the irradiance
level drops below 8 μW/cm2/nm or at any point during
the day during a rainy/cloudy day when the irradiance
stays below 8 μW/cm2/nm. If the irradiance persists
below 8 μW/cm2/nm for more than 1 hour and the in-
fant qualifies for PT per the AAP guideline, CPT will be
initiated. If the irradiance again exceeds 8 μW/cm2/nm
then the infant may again be placed in FS-PT.
Treatment canopies
Two FS-PT canopies will be used: one fitted with the
Gila Titanium film and the other fitted with the Air Blue
80 film because of concerns about irradiance and heat.
The Titanium canopy transmits approximately 33% blue
light in the wavelength range 400 to 520 nm with much
lower heat and will be used during sunny periods of the
day. The Air Blue canopy transmits roughly 79% blue
light as well as heat and will be used during cooler over-
cast periods of the day. The infants will be moved from
one canopy to the other as needed during the day, when
the weather changes, with the goal of keeping the irradi-
ance level above 8 μW/cm2/nm. The irradiance will be
measured at an infant’s abdomen level with a Bili-
Blanket Meter II every half hour in infants under FS-PT
(if possible, additional measurements may be done) and
daily in those infants under CPT.
The proportion of blue light accessible to the subjects
under FS-PT canopies is dependent on the location of
treatment canopies in relation to surrounding buildings. It
is therefore imperative that the treatment canopies be
placed in a location with proven day-long sun exposure
throughout the year, preferably one also protected from
potentially violent wind currents and surface dust gener-
ated by traffic. In fact, the single most important reason
for replacing films is wind damage. A roof top terrace,
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factory location. A courtyard of adequate size surrounded
by low buildings could be even more suitable. Finally, per-
haps most ideal and practical, will be the construction of a
suitable FS-PT room or a small permanent building with
a glass or plexiglass roof, in an appropriately “sunny” part
of a hospital. This would be a most ideal solution to pre-
vent issues with wind, dust, security, and so forth. How-
ever, such a treatment facility may overtax local resources.
Treatment duration
Generally, the infants will be placed under FS-PT/CPT
from 9:00 am to 5:00 pm (target minimum duration of
5 hours per day for any infant in the study at 10:00 am,
or 65% of total time between start time and 5:00 pm for
infants enrolled after 10:00 am). The infants’ eyes will be
protected with low-cost eye covers made from the elastic
tops of any color socks. Bilirubin kinetics will only be
calculated for infants who are able to spend at least
5 hours in FS-PT/CPT.
Temperature measurements
Infant temperature will be measured hourly while under
FS-PT and CPT and monitored based on World Health
Organization guidelines for normothermia, hypothermia,
and hyperthermia [30]. For the purpose of this study the
normal temperature range of 36.5 to 37.5°C [30] was
modified slightly to 35.5 to 38.0°C in consultation with a
neonatologist to provide a broader but safe temperature
limit for term and near-term infants. In addition, during
the prior safety and efficacy observational study in which
infants were monitored closely, no untoward effects
of temperatures within the chosen range were re-
ported. If the axillary body temperature falls below
35.5°C the infant will be placed skin-to-skin with the
mother and/or brought inside until the temperature
returns to the normal range of 35.5 to 38.0°C. If the
axillary body temperature goes above 38.0°C, the infant
will be brought indoors and/or placed in the shade and/
or placed on a wet towel until the body temperature
returns to normal at which time FS-PT will resume. The
time it takes to return to normal will be recorded. Infants
who do not return to normothermia within 1 hour will
be taken out of FS-PT for that day. If the axillary body
temperature falls below 35°C the infant will be placed
skin-to-skin with the mother or wrapped well and
brought inside until the temperature returns to normal.
If the axillary body temperature goes above 39.0°C, the
infant will be brought indoors and placed on a wet towel
until the body temperature returns to normal at which
time FS-PT will resume. The time it takes to return to
normal will be recorded. Infants who do not return to
normothermia within 1 hour will be taken out of FS-PT
for that day. Infants whose axillary body temperature fallbelow 35°C or exceed 39°C on two occasions will be ex-
cluded from the study.
Dehydration
The nurse will also check hourly for clinical signs of
dehydration in the form of dry mucus membranes,
sunken eyes, dry eyes, and skin tenting. The physician
may elect to increase the mother’s breastfeeding fre-
quency while continuing with the FS-PT if the diag-
nosis is mild dehydration. Whenever the diagnosis of
moderate or severe dehydration is made, the infant
will be withdrawn from the study for treatment. Be-
cause both nutrition and hydration are important in
the prevention and treatment of severe NNJ, infants
will be allowed and encouraged to breastfeed ad lib
and often. The FS-PT canopy allows for the mother
to stay with the infant and to feed as often as she de-
sires. Mothers will be comfortably seated on custom-
made reclined chairs (painted white) and provided with
white aprons for breast-feeding or when they need to
carry their babies (Figure 1C). If the mother has chosen
to use artificial feeds, those will also be allowed and en-
couraged ad lib. For CPT, the mother will be allowed and
encouraged to take the infant out as needed for bathing
or feeding.
Sunburn
The nurse will assess for sunburn by looking for the
onset of pink skin every hour. Most infants are born
relatively light skinned and darken over time. Infants
born very dark and for whom it would be difficult to
recognize pink skin are also much less likely to become
sunburned. Absence of sunburn determined in consult-
ation with a dermatologist is defined as the absence of
new-onset pink skin. If the infant has the onset of pink
skin, the attending physician will be notified and will
verify the finding. If the physician makes the diagnosis of
sunburn, the infant will be immediately withdrawn from
the study. Mothers will be allowed and encouraged as
much as possible to stay with their babies, but will be
able to leave as needed to care for themselves or other
needs. Study nurses will care for the infants during their
mother’s absence.
Treatment efficacy
Efficacy will be tested by measuring TSB levels prior to
the placement of the infant under PT each morning to
establish baseline TSB levels. Infants with morning TSB
levels that meet the criteria for PT will be randomized
for FS-PT. Repeat TSB levels will be obtained at the end
of each day spent under FS-PT and between ~4:00 to
5:00 pm for infants under CPT to estimate the effective-
ness of the treatment for the day and to determine if the
requirement for night-time PT is met.
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Data will be collected on paper case report forms and
entered via a web interface into a secure database. The
study data will be collected and managed using REDCap
(Research Electronic Data Capture) electronic data capture
tools hosted at the University of Minnesota’s Academic
Health Center. REDCap is a secure, web-based application
designed to support data capture for research studies, pro-
viding: 1) an intuitive interface for validated data entry;
2) audit trails for tracking data manipulation and export
procedures; 3) automated export procedures for seamless
data downloads to common statistical packages; and
4) procedures for importing data from external sources.
Demographic data will be summarized and compared
between the treatment and control groups using appro-
priate methods, such as Pearson’s chi-square test for cat-
egorical variables and two-sample t-tests for continuous
variables. The primary objective is to compare the effi-
cacy of FS-PT and CPT. A 95% exact binomial confi-
dence interval for the true difference in efficacy between
the FS-PT treated and CPT control groups will be calcu-
lated. FS-PT will be deemed non-inferior to CPT if the
calculated confidence interval does not extend more
than 10% below the equivalence point.
We plan to conduct three distinct analyses: an intent-
to-treat analysis based on the assigned treatment for
each enrolled infant, an as-treated analysis based on the
actual treatment received on a given day and a per-
protocol analysis including only enrolled infants who
received the assigned treatment on all of their treat-
ment days.
Safety monitoring and adverse events
The Principal Investigator will oversee the safety of the
study, including careful assessment and appropriate
reporting of adverse events to relevant authorities at
IMH. All anticipated adverse events such as sunburn,
dehydration, and temperature instability as well as un-
anticipated adverse events occurring during the study
period will be recorded and closely monitored. Medical
monitoring will include a regular assessment of the
number and type of serious adverse events. The clinical
course of each event will be followed until resolution,
stabilization, or until it has been determined that study
treatment or participation is not the cause.
All observed or volunteered adverse effects and abnor-
mal test findings, regardless of treatment group, if applic-
able, or suspected causal relationship to the investigational
device or, if applicable, other study treatment or diagnostic
product(s) will be recorded in the subjects’ case histories.
For all adverse effects, sufficient information will be pur-
sued and/or obtained so as to permit: 1) an adequate deter-
mination of the outcome of the effect (that is, whether the
effect should be classified as a serious adverse effect); and2) an assessment of the casual relationship between the ad-
verse effect and the investigational device or, if applicable,
the other study treatment or diagnostic product(s).
Ethical considerations
This study was approved by the IRBs/Ethical Commit-
tees at the University of Minnesota, Minnesota Medical
Research Foundation (Hennepin County Medical Center),
and the Lagos State Government. This study is being
conducted according to United States and international
standards of Good Clinical Practice (21 CFR 812 and Inter-
national Conference on Harmonization guidelines), applic-
able government regulations and Institutional research
policies and procedures. The parents/guardians of poten-
tial subjects for this study will be provided a consent form
describing this study and providing sufficient information
for the parents/guardians to make an informed decision
about their child’s participation in this study. The consent
form has been submitted with the protocol for review
and approval by the relevant IRBs/Ethical Committees
for the study. The formal consent of a parent/guardian,
using the IRB-approved consent form, will be obtained
before the infant is subjected to any study procedure.
This consent form will be signed or thumb-printed by
the parent/guardian, and the investigator-designated re-
search professional obtaining the consent. A blank copy
of the IRB-approved form will be kept on-site and by
the sponsor-investigator.
Trial status
The first participant was randomized on 29 November
2012 and recruitment is ongoing as of 31 July 2013.
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